Modulation of Remifentanil-induced Postinfusion Hyperalgesia

Summary

In addition to alleviate pain there is growing evidence that µ-opioids enhance pain. This problem is known as opioid induced hyperalgesia(OIH).The NMDA receptor is involved in opioid induced hyperalgesia it may be possible to block OIH by cyclooxygenase inhibitors. This has been demonstrated with parecoxib, a COX-II inhibitor, in a experimental pain model.Both COX-1 and COX-2 are expressed in the spinal cord. It would be of interest to investigate whether a COX-1 preferring inhibitor like ketorolac also can reduce opioid induced hyperalgesic in this experimental pain model.

Conditions

• Hyperalgesia, Secondary

Interventions

OTHER

Placebo

Placebo IV before placebo infusion

DRUG

Remifentanil

placebo IV and remifentanil infusion

DRUG

Ketorolac and remifentanil

Ketorolac IV and remifentanil infusion

DRUG

Parecoxib and remifentanil

Parecoxib IV and remifentanil infusion

Sponsors & Collaborators

• University of Oslo

  collaborator OTHER

• Rikshospitalet University Hospital

  collaborator OTHER

• Ullevaal University Hospital

  lead OTHER

Principal Investigators

• Harald Lenz, MD · Ullevaal University Hospital

• Johan Raeder, Prof.,MD,PhD · Ullevaal University Hospital

• Audun Stubhaug, Prof.,MD,PhD · Rikshospitalet University Hospital

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

MALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2008-12-31

Primary Completion

2009-04-30

Completion

2009-04-30

Countries

• Norway

Study Locations